“…Most published studies seeking to recapitulate a clinical cisplatin treatment paradigm have employed an acute exposure model (Bieber et al , 2006; Delbes et al , 2009; Favareto et al , 2011; Ilbey et al , 2009a; Ilbey et al , 2009b; Marcon, Hales and Robaire, 2008; Seethalakshmi et al , 1992). The treatment model in this study differs from the reports that do use a multi cycle regimen in a number of critical variables: the species and age of the model organism, the daily dose, the cumulative dose, the length and number of exposure cycles and recovery periods, the vehicle, the administration route, and other compounds given in concert with cisplatin (Bieber, Marcon, Hales and Robaire, 2006; Delbes, Chan, Pakarinen, Trasler, Hales and Robaire, 2009; Favareto, Fernandez, da Silva, Anselmo-Franci and Kempinas, 2011; Ilbey, Ozbek, Cekmen, Simsek, Otunctemur and Somay, 2009a; Ilbey, Ozbek, Simsek, Cekmen, Otunctemur and Somay, 2009b; Marcon, Hales and Robaire, 2008; Seethalakshmi, Flores, Kinkead, Carboni, Malhotra and Menon, 1992). Chiefly, the multi-cycle cisplatin paradigm utilized in this study closely simulates the manner in which cisplatin is administered clinically, conforming to prescribed daily and cumulative dose, length and timing of dosing and recovery periods, and number of cycles (Sawhney, Giammona, Meistrich and Richburg, 2005) (Figure 1).…”